跳至主要内容
临床试验/NCT01460836
NCT01460836已完成不适用

Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis

Novartis Pharmaceuticals0 个研究点开始时间: 2010年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
主要终点
Mean relative change in Forced Expiratory Volume in 1 second (FEV1) from baseline

研究概览

简要总结

Matching-adjusted indirect comparison of tobramycin solution (TIS) versus aztreonam lysine (AZLI) using TIS patient level clinical trial data and AZLI aggregated clinical trial data from published literature.

研究设计

研究类型
Observational
时间视角
Retrospective

入排标准

年龄范围
6 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥ 6 years of age with a documented Cystic fibrosis (CF) diagnosis,
  • moderate-to severe lung disease,
  • the ability to perform reproducible pulmonary function tests,
  • Pseudomonas aeruginosa (PA) airway infection.

排除标准

  • Other protocol-defined inclusion/exclusion criteria may apply.

研究组 & 干预措施

Tobramycin Solution

干预措施: Tobramycin solution for inhalation (Drug)

Aztreonam lysine

干预措施: Aztreonam lysine for inhalation (Drug)

结局指标

主要结局

Mean relative change in Forced Expiratory Volume in 1 second (FEV1) from baseline

时间窗: Baseline, Weeks 2, 4 and 6

次要结局

  • Mean change in the density of Pseudomonas aeruginosa (PA) from baseline(Baseline, Weeks 2, 4 and 6)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验